There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA – Research Report) and Century Therapeutics (IPSC – Research Report) with bullish sentiments.
Don’t Miss Our New Year’s Offers:
MetaVia (MTVA)
MetaVia received a Buy rating and a $12.00 price target from H.C. Wainwright analyst Ed Arce on December 27. The company’s shares closed last Friday at $1.76, close to its 52-week low of $1.51.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.2% and a 47.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, NewAmsterdam Pharma Company, and Ultragenyx Pharmaceutical.
MetaVia has an analyst consensus of Moderate Buy, with a price target consensus of $11.00, representing a 525.0% upside. In a report issued on December 19, Maxim Group also reiterated a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Century Therapeutics (IPSC)
Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Century Therapeutics today and set a price target of $4.00. The company’s shares closed last Friday at $1.04, close to its 52-week low of $0.95.
According to TipRanks.com, Tenthoff ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.9% and a 27.4% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Century Therapeutics with a $4.50 average price target.
Read More on MTVA: